Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. ETF
  3. AVBP
AVBP logo

AVBP

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

AVBP News

ARRIVENT BIOPHARMA INC: B. RILEY INCREASES TARGET PRICE FROM $37 TO $45

Mar 23 2026moomoo

Aarvik to Present Novel ADCs at AACR Annual Meeting 2026

Mar 17 2026Newsfilter

Surge in Options Trading Volume for Alphabet and ArriVent

Mar 06 2026NASDAQ.COM

ArriVent Biopharma Reports Increased Annual Loss

Mar 06 2026NASDAQ.COM

ArriVent BioPharma Reports FY EPS Beat

Mar 05 2026seekingalpha

Growth Prospects for the EGFR-NSCLC Market Analyzed

Feb 11 2026Newsfilter

Oncolytics Biotech Receives FDA Fast Track Designation

Feb 05 2026PRnewswire

FDA Accelerates Oncology Drug Approvals, Boosting Market Potential

Feb 05 2026Newsfilter

Oncolytics Biotech Advances Pelareorep for Anal Cancer with 29% Response Rate

Jan 12 2026PRnewswire

Oncolytics Biotech Advances Pelareorep for Anal Cancer with 29% Response Rate

Jan 12 2026Newsfilter

Oncolytics Biotech Achieves 33% Response Rate in KRAS-Mutant Colorectal Cancer

Dec 16 2025Newsfilter

Oncolytics Biotech Achieves 33% Response Rate in KRAS-Mutant Colorectal Cancer

Dec 16 2025PRnewswire

Top Analysts Recommend 3 Best Stocks to Purchase Now, 9/10/2025

Sep 10 2025TipRanks

Arrivent Unveils Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Lung Cancer Conference

Sep 09 2025Newsfilter

Explore the Potential: XBI Could Rise by 55%

Aug 22 2025NASDAQ.COM

Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $33

Aug 12 2025Benzinga